Wall Street analysts forecast that Novo Nordisk A/S (NYSE:NVO) will post earnings of $0.61 per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Novo Nordisk A/S’s earnings. Novo Nordisk A/S reported earnings per share of $0.62 during the same quarter last year, which would indicate a negative year-over-year growth rate of 1.6%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, November 7th.

On average, analysts expect that Novo Nordisk A/S will report full-year earnings of $2.52 per share for the current financial year, with EPS estimates ranging from $2.49 to $2.55. For the next financial year, analysts expect that the firm will report earnings of $2.56 per share, with EPS estimates ranging from $2.50 to $2.61. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Novo Nordisk A/S.

A number of research analysts have weighed in on the stock. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Monday, July 2nd. Zacks Investment Research raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, July 31st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $64.00.

A number of institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 27,685 shares of the company’s stock worth $1,485,000 after purchasing an additional 1,070 shares during the period. Oxbow Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 3.8% during the 1st quarter. Oxbow Advisors LLC now owns 32,296 shares of the company’s stock worth $1,591,000 after purchasing an additional 1,190 shares during the period. Wedbush Securities Inc. increased its holdings in shares of Novo Nordisk A/S by 3.3% during the 2nd quarter. Wedbush Securities Inc. now owns 39,181 shares of the company’s stock worth $1,807,000 after purchasing an additional 1,253 shares during the period. HighVista Strategies LLC increased its holdings in shares of Novo Nordisk A/S by 4.1% during the 1st quarter. HighVista Strategies LLC now owns 32,700 shares of the company’s stock worth $1,610,000 after purchasing an additional 1,300 shares during the period. Finally, Boston Common Asset Management LLC increased its holdings in shares of Novo Nordisk A/S by 0.9% during the 2nd quarter. Boston Common Asset Management LLC now owns 149,793 shares of the company’s stock worth $6,908,000 after purchasing an additional 1,391 shares during the period. 6.75% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S stock opened at $47.87 on Wednesday. The firm has a market cap of $114.53 billion, a price-to-earnings ratio of 20.46, a PEG ratio of 2.52 and a beta of 0.66. Novo Nordisk A/S has a fifty-two week low of $44.28 and a fifty-two week high of $58.37.

The company also recently announced a special dividend, which will be paid on Tuesday, August 28th. Shareholders of record on Monday, August 20th will be given a dividend of $0.4669 per share. This represents a yield of 1.72%. The ex-dividend date of this dividend is Friday, August 17th. Novo Nordisk A/S’s dividend payout ratio is 38.89%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Further Reading: Leveraged Buyout (LBO)

Get a free copy of the Zacks research report on Novo Nordisk A/S (NVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.